Myomo (NYSEAMERICAN:MYO – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $9.90 million for the quarter.
Myomo Price Performance
Shares of MYO opened at $5.13 on Thursday. Myomo has a one year low of $2.51 and a one year high of $7.17. The company has a market cap of $155.18 million, a price-to-earnings ratio of -22.30 and a beta of 1.68.
Wall Street Analyst Weigh In
MYO has been the topic of a number of research reports. Ascendiant Capital Markets boosted their price objective on Myomo from $8.50 to $9.00 and gave the stock a “buy” rating in a research report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $7.50 price objective on shares of Myomo in a research report on Wednesday, November 13th. Finally, Craig Hallum boosted their price objective on Myomo from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Friday, December 13th.
Myomo Company Profile
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.
Recommended Stories
- Five stocks we like better than Myomo
- How to trade penny stocks: A step-by-step guide
- Buffett’s on the Sidelines – Should You Follow?
- What is a Stock Market Index and How Do You Use Them?
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.